Physician profile
Heather Arnold
NPI 1932351269
$2,677.63
in general payments reported to CMS, 2019-2025
20 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $690 · 2022: $658 · 2023: $518 · 2024: $480 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $586.18 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $305.49 | 2021-2025 | |
| Boston Scientific Corporation | $298.07 | 2023-2025 | Watchman Flx, General - Therapies, Bodyguardian |
| Merck Sharp & Dohme LLC | $194.65 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $183.99 | 2021-2023 | Farxiga, Andexxa |
| Janssen Pharmaceuticals, INC | $183.97 | 2021-2023 | Xarelto |
| Atricure, INC. | $129.11 | 2021-2022 | |
| Amgen INC. | $128.52 | 2022-2025 | Repatha, Repatha |
| Biotronik INC. | $127.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.31 | 2022-2023 | Jardiance |
| Pfizer INC. | $111.63 | 2022-2025 | |
| Edwards Lifesciences Corporation | $70.28 | 2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Impulse Dynamics (USA) INC. | $63.91 | 2023-2025 | Optimizer, Optimizer |
| Abiomed | $42.74 | 2024-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $27.06 | 2025 | Onpattro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.40 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $21.14 | 2023 | Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $21.11 | 2024 | Arcalyst |
| Teleflex LLC | $20.86 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.